Optimizing mRNA Vaccines and Virus-Mediated CAR T-Cell Therapy for Immuno-Oncology
POSTER
Optimizing mRNA Vaccines and Virus-Mediated CAR T-Cell Therapy for Immuno-Oncology
With the success of mRNA vaccines during the COVID-19 pandemic and CAR T-cell therapies in clinical trials, there is growing opportunity for immunotherapies in the treatment of many types of cancers. Lentiviral vectors have proven effective at delivery of genetic material or gene editing technology for ex vivo processing, but the benefits and promise of Adeno-associated virus (AAV) and mRNA tools for in vivo immunotherapy have garnered recent interest. In this poster, we present streamlined approaches for lentiviral, AAV, and mRNA production that improves data quality through innovative synthesis and sequencing methodologies as compared to current standards.
